HAEMONETICS ($HAE) posted quarterly earnings results on Thursday, November 6th. The company reported earnings of $1.27 per share, beating estimates of $1.12 by $0.15. The company also reported revenue of $327,320,000, beating estimates of $314,513,293 by $12,806,707.
You can see Quiver Quantitative's $HAE stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
HAEMONETICS Hedge Fund Activity
We have seen 148 institutional investors add shares of HAEMONETICS stock to their portfolio, and 173 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VICTORY CAPITAL MANAGEMENT INC added 761,851 shares (+4488.9%) to their portfolio in Q2 2025, for an estimated $56,841,703
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 600,702 shares (-27.4%) from their portfolio in Q2 2025, for an estimated $44,818,376
- BARROW HANLEY MEWHINNEY & STRAUSS LLC added 480,834 shares (+inf%) to their portfolio in Q2 2025, for an estimated $35,875,024
- WELLINGTON MANAGEMENT GROUP LLP removed 478,594 shares (-18.2%) from their portfolio in Q2 2025, for an estimated $35,707,898
- UBS GROUP AG added 453,692 shares (+109.0%) to their portfolio in Q2 2025, for an estimated $33,849,960
- CAPITAL RESEARCH GLOBAL INVESTORS removed 438,280 shares (-27.8%) from their portfolio in Q2 2025, for an estimated $32,700,070
- AQR CAPITAL MANAGEMENT LLC added 275,683 shares (+157.9%) to their portfolio in Q2 2025, for an estimated $20,568,708
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
HAEMONETICS Government Contracts
We have seen $97,583 of award payments to $HAE over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- BLOOD ADDITIVE SOLUTION FOR NAVAL HOSPITAL GUAM: $23,519
- HAEMONETICS EQUIPMENT SERVICE MAINT: $23,244
- EXPRESS REPORT: EXPRESS REPORT: NX ORDERS PLACED DURING THE MONTHS OF JAN-MAY 2025.: $22,660
- (R) HAEMONETICS CORPORATION:1177264 [25-002935] AUTOMATED CELL PROCESSORS ACP 215 SERIAL NUMBER 19C027SPG ...: $12,166
- HAEMONETICS CORPORATION:1177264 [24-006940]: $8,148
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
HAEMONETICS Analyst Ratings
Wall Street analysts have issued reports on $HAE in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barrington Research issued a "Outperform" rating on 10/21/2025
- Citigroup issued a "Buy" rating on 10/07/2025
- Raymond James issued a "Outperform" rating on 08/11/2025
- Needham issued a "Buy" rating on 08/07/2025
- Baird issued a "Outperform" rating on 06/26/2025
- JMP Securities issued a "Market Outperform" rating on 05/20/2025
To track analyst ratings and price targets for HAEMONETICS, check out Quiver Quantitative's $HAE forecast page.
HAEMONETICS Price Targets
Multiple analysts have issued price targets for $HAE recently. We have seen 8 analysts offer price targets for $HAE in the last 6 months, with a median target of $74.0.
Here are some recent targets:
- Michael Petusky from Barrington Research set a target price of $86.0 on 10/21/2025
- Joanne Wuensch from Citigroup set a target price of $64.0 on 10/07/2025
- Andrew Cooper from Raymond James set a target price of $78.0 on 08/11/2025
- Anthony Petrone from Mizuho set a target price of $70.0 on 08/08/2025
- Rohin Patel from JP Morgan set a target price of $62.0 on 08/08/2025
- Mike Matson from Needham set a target price of $68.0 on 08/07/2025
- David Rescott from Baird set a target price of $87.0 on 06/26/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
